Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Sota Yamaguchi to Assume New ASKA President Post in June
April 27, 2021
- Canada Starts Review of Medicago’s Rolling Submission for COVID-19 Vaccine
April 27, 2021
- Sumitomo Dainippon Ups FY2020 Guidance
April 26, 2021
- Lenvima/Keytruda Combo Filed for Uterine Body Cancer in Japan
April 26, 2021
- Gilead Seeks UC Indication for JAK Inhibitor Jyseleca in Japan
April 26, 2021
- Takeda’s ALK Inhibitor Alunbrig Now Available in Japan
April 26, 2021
- Santen to Launch New Plant in China, Commence Operations in 2025
April 26, 2021
- Delta-Fly/Nippon Chemiphar’s TME Therapy Now in Japan PII Trial
April 23, 2021
- Nichi-Iko Reveals Possible Supply Delays for 164 Products, Stirs Confusion at Peers, Customers
April 23, 2021
- Chugai’s Q1 Sales Slide 5.9% on Drug Price Cuts, Gx, Frontloaded Actemra Exports
April 23, 2021
- Stella Pharma Goes Public on TSE
April 23, 2021
- Mitsubishi Tanabe Files Tardive Dyskinesia Drug in Japan
April 23, 2021
- Chugai Eyes Japan Submission for COVID-19 Antibody Cocktail by Year-End
April 23, 2021
- Takeda Teams Up with IT Startup for AI-Driven Early HAE Detection
April 23, 2021
- Kobayashi Kako Starts Recalling Products Subject to Approval Revocation
April 22, 2021
- Calquence, Adlumiz, Zymso Now Available in Japan
April 22, 2021
- Supply Delays Likely for 160 Nichi-Iko Products despite Biz Suspension Lifted
April 22, 2021
- Fujifilm Launches New Japanese Avigan PIII Study for COVID-19
April 22, 2021
- MSD Japan Suffers 7% Sales Dip on Repeated Keytruda Re-Pricing, Urges Policy Rethink
April 21, 2021
- FDA Accepts Astellas/Seagen’s Submissions for Padcev’s Full Approval, Label Expansion
April 21, 2021
ページ
More than a year after Dupixent (dupilumab) became the first antibody therapy approved for COPD in Japan, drug makers are…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…